FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131759566> ?p ?o ?g. }

• W3131759566 endingPage "2087" @default.
• W3131759566 startingPage "2067" @default.
• W3131759566 abstract "The transforming growth factor-beta (TGF-β) signaling pathway is the predominant cytokine signaling pathway in the development and progression of hepatocellular carcinoma (HCC). Bone morphogenetic protein (BMP), another member of the TGF-β superfamily, has been frequently found to participate in crosstalk with the TGF-β pathway. However, the complex interaction between the TGF-β and BMP pathways has not been fully elucidated in HCC. We found that the imbalance of TGF-β1/BMP-7 pathways was associated with aggressive pathological features and poor clinical outcomes in HCC. The induction of the imbalance of TGF-β1/BMP-7 pathways in HCC cells could significantly promote HCC cell invasion and stemness by increasing inhibitor of differentiation 1 (ID1) expression. We also found that the microRNA (miR)-17-92 cluster, originating from the extracellular vesicles (EVs) of M2-polarized tumor-associated macrophages (M2-TAMs), stimulated the imbalance of TGF-β1/BMP-7 pathways in HCC cells by inducing TGF-β type II receptor (TGFBR2) post-transcriptional silencing and inhibiting activin A receptor type 1 (ACVR1) post-translational ubiquitylation by targeting Smad ubiquitylation regulatory factor 1 (Smurf1). In vivo, short hairpin (sh)-MIR17HG and ACVR1 inhibitors profoundly attenuated HCC cell growth and metastasis by rectifying the imbalance of TGF-β1/BMP-7 pathways. Therefore, we proposed that the imbalance of TGF-β1/BMP-7 pathways is a feasible prognostic biomarker and recovering the imbalance of TGF-β1/BMP-7 pathways might be a potential therapeutic strategy for HCC. The transforming growth factor-beta (TGF-β) signaling pathway is the predominant cytokine signaling pathway in the development and progression of hepatocellular carcinoma (HCC). Bone morphogenetic protein (BMP), another member of the TGF-β superfamily, has been frequently found to participate in crosstalk with the TGF-β pathway. However, the complex interaction between the TGF-β and BMP pathways has not been fully elucidated in HCC. We found that the imbalance of TGF-β1/BMP-7 pathways was associated with aggressive pathological features and poor clinical outcomes in HCC. The induction of the imbalance of TGF-β1/BMP-7 pathways in HCC cells could significantly promote HCC cell invasion and stemness by increasing inhibitor of differentiation 1 (ID1) expression. We also found that the microRNA (miR)-17-92 cluster, originating from the extracellular vesicles (EVs) of M2-polarized tumor-associated macrophages (M2-TAMs), stimulated the imbalance of TGF-β1/BMP-7 pathways in HCC cells by inducing TGF-β type II receptor (TGFBR2) post-transcriptional silencing and inhibiting activin A receptor type 1 (ACVR1) post-translational ubiquitylation by targeting Smad ubiquitylation regulatory factor 1 (Smurf1). In vivo, short hairpin (sh)-MIR17HG and ACVR1 inhibitors profoundly attenuated HCC cell growth and metastasis by rectifying the imbalance of TGF-β1/BMP-7 pathways. Therefore, we proposed that the imbalance of TGF-β1/BMP-7 pathways is a feasible prognostic biomarker and recovering the imbalance of TGF-β1/BMP-7 pathways might be a potential therapeutic strategy for HCC." @default.
• W3131759566 created "2021-03-01" @default.
• W3131759566 creator A5000991048 @default.
• W3131759566 creator A5003226007 @default.
• W3131759566 creator A5008367011 @default.
• W3131759566 creator A5012394408 @default.
• W3131759566 creator A5025362555 @default.
• W3131759566 creator A5031069096 @default.
• W3131759566 creator A5050456659 @default.
• W3131759566 creator A5051576557 @default.
• W3131759566 creator A5061753178 @default.
• W3131759566 creator A5063650098 @default.
• W3131759566 creator A5068348950 @default.
• W3131759566 creator A5076930880 @default.
• W3131759566 creator A5089019310 @default.
• W3131759566 date "2021-06-01" @default.
• W3131759566 modified "2023-10-18" @default.
• W3131759566 title "Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness" @default.
• W3131759566 cites W1038682962 @default.
• W3131759566 cites W1492716968 @default.
• W3131759566 cites W1965147416 @default.
• W3131759566 cites W1968234490 @default.
• W3131759566 cites W1990225108 @default.
• W3131759566 cites W2000799034 @default.
• W3131759566 cites W2003599465 @default.
• W3131759566 cites W2026025275 @default.
• W3131759566 cites W2027847170 @default.
• W3131759566 cites W2029683042 @default.
• W3131759566 cites W2033455982 @default.
• W3131759566 cites W2050637252 @default.
• W3131759566 cites W2052181632 @default.
• W3131759566 cites W2056030683 @default.
• W3131759566 cites W2059073003 @default.
• W3131759566 cites W2078107700 @default.
• W3131759566 cites W2085114559 @default.
• W3131759566 cites W2087340587 @default.
• W3131759566 cites W2088611209 @default.
• W3131759566 cites W2101417534 @default.
• W3131759566 cites W2111063080 @default.
• W3131759566 cites W2112903125 @default.
• W3131759566 cites W2123927899 @default.
• W3131759566 cites W2130870648 @default.
• W3131759566 cites W2140173180 @default.
• W3131759566 cites W2158913105 @default.
• W3131759566 cites W2161918376 @default.
• W3131759566 cites W2163482178 @default.
• W3131759566 cites W2164455778 @default.
• W3131759566 cites W2166920557 @default.
• W3131759566 cites W2168472139 @default.
• W3131759566 cites W2169746680 @default.
• W3131759566 cites W2171262765 @default.
• W3131759566 cites W2173157151 @default.
• W3131759566 cites W2339890238 @default.
• W3131759566 cites W2343938601 @default.
• W3131759566 cites W2428705285 @default.
• W3131759566 cites W2592339836 @default.
• W3131759566 cites W2597164018 @default.
• W3131759566 cites W2748983493 @default.
• W3131759566 cites W2749037511 @default.
• W3131759566 cites W2756331708 @default.
• W3131759566 cites W2768241957 @default.
• W3131759566 cites W2772748863 @default.
• W3131759566 cites W2782567045 @default.
• W3131759566 cites W2788142646 @default.
• W3131759566 cites W2790006964 @default.
• W3131759566 cites W2791327106 @default.
• W3131759566 cites W2791378117 @default.
• W3131759566 cites W2803788332 @default.
• W3131759566 cites W2809245892 @default.
• W3131759566 cites W2883225927 @default.
• W3131759566 cites W2889646458 @default.
• W3131759566 cites W2906577547 @default.
• W3131759566 cites W2916609106 @default.
• W3131759566 cites W2945116833 @default.
• W3131759566 cites W2952163200 @default.
• W3131759566 cites W2952189825 @default.
• W3131759566 cites W2982974693 @default.
• W3131759566 cites W2986360195 @default.
• W3131759566 cites W2999516544 @default.
• W3131759566 cites W3015758463 @default.
• W3131759566 cites W3032499737 @default.
• W3131759566 cites W3037860162 @default.
• W3131759566 cites W3089978889 @default.
• W3131759566 doi "https://doi.org/10.1016/j.ymthe.2021.02.016" @default.
• W3131759566 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8178441" @default.
• W3131759566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33601054" @default.
• W3131759566 hasPublicationYear "2021" @default.
• W3131759566 type Work @default.
• W3131759566 sameAs 3131759566 @default.
• W3131759566 citedByCount "30" @default.
• W3131759566 countsByYear W31317595662021 @default.
• W3131759566 countsByYear W31317595662022 @default.
• W3131759566 countsByYear W31317595662023 @default.
• W3131759566 crossrefType "journal-article" @default.
• W3131759566 hasAuthorship W3131759566A5000991048 @default.
• W3131759566 hasAuthorship W3131759566A5003226007 @default.
• W3131759566 hasAuthorship W3131759566A5008367011 @default.
• W3131759566 hasAuthorship W3131759566A5012394408 @default.

• next